Recommendations for follow up in castration resistant prostate cancer

被引:0
|
作者
Vazquez-Alonso, Fernando [1 ]
Puche-Sanz, Ignacio [1 ]
Manuel Cozar-Olmo, Jose [1 ]
机构
[1] Hosp Univ Virgen Nieves, UGC Urol, Avda Fuerzas Armadas 2, Granada 18014, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2018年 / 71卷 / 08期
关键词
Prostate cancer; Diagnosis; Follow up; Castration resistance; Metastases; CLINICAL-TRIALS; FREE SURVIVAL; PHASE-II; ENZALUTAMIDE; ABIRATERONE; GUIDELINES; DISEASE; DESIGN; PET/CT; MEN;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: There is no broad consensus about what diagnostic tests use for CRPC follow up as well as their frequency. Our objective is to review and analyze the most important CRPC follow up patterns described in the literature to date. METHODS: We performed a critical analysis of the recommendations for follow up most universally employed (PCWG3, RADAR, St Gallen consensus, NCCN guidelines, EAU guidelines) RESULTS: CT scan and bone scan are the routine recommended diagnostic tests, in front of other techniques such as PET/CT or MRI, that may improve the diagnostic efficacy but they have the problem of availability and lack of internal validity for follow up. CONCLUSIONS: Follow up is different for non metastatic and metastatic CRPC. For nm CRPC, it is recommended to perform monitoring that includes PSA and imaging tests, without consensus about periodicity. For mCRPC, it is recammendable to do follow up with periodic PSA and imaging tests, since it is possible to have radiological progression without PSA progression.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [41] Novel hormonal therapy for castration-resistant prostate cancer
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2012, 23 : 259 - 263
  • [42] Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients
    Buonerba, Carlo
    Federico, Piera
    Bosso, Davide
    Puglia, Livio
    Policastro, Tania
    Izzo, Michela
    Perri, Francesco
    Scarpati, Giuseppina Della Vittoria
    Ferro, Matteo
    De Cobelli, Ottavio
    De Placido, Sabino
    Aieta, Michele
    Imbimbo, Ciro
    Longo, Nicola
    Di Lorenzo, Giuseppe
    FUTURE ONCOLOGY, 2014, 10 (08) : 1353 - 1360
  • [43] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [44] Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best?
    Heidegger, Isabel
    Brandt, Maximilian P.
    Heck, Matthias M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (04) : 129 - 136
  • [45] Emerging therapies in castration resistant prostate cancer
    Thoreson, Gregory R.
    Gayed, Bishoy A.
    Chung, Paul H.
    Raj, Ganesh V.
    CANADIAN JOURNAL OF UROLOGY, 2014, 21 : 98 - 105
  • [46] Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression
    Ruchalski, Kathleen
    Kim, Hyun J.
    Douek, Michael
    Raman, Steven
    Patel, Maitraya
    Sai, Victor
    Gutierrez, Antonio
    Levine, Benjamin
    Fischer, Cheryce
    Allen-Auerbach, Martin
    Gupta, Pawan
    Coy, Heidi
    Villegas, Bianca
    Brown, Matthew
    Goldin, Jonathan
    CANCER IMAGING, 2022, 22 (01)
  • [47] The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
    Geethakumari, Praveen Ramakrishnan
    Cookson, Michael S.
    Kelly, William Kevin
    ONCOLOGY-NEW YORK, 2016, 30 (02): : 187 - +
  • [48] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [49] The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
    Crippa, Alessio
    De Laere, Bram
    Discacciati, Andrea
    Larsson, Berit
    Connor, Jason T.
    Gabriel, Erin E.
    Thellenberg, Camilla
    Janes, Elin
    Enblad, Gunilla
    Ullen, Anders
    Hjalm-Eriksson, Marie
    Oldenburg, Jan
    Ost, Piet
    Lindberg, Johan
    Eklund, Martin
    Gronberg, Henrik
    TRIALS, 2020, 21 (01) : 579
  • [50] Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer
    Wang, Zhu
    Wu, Dinglan
    Ng, Chi-Fai
    Teoh, Jeremy Yuen-Chun
    Yu, Shan
    Wang, Yuliang
    Chan, Franky L.
    ENDOCRINE-RELATED CANCER, 2018, 25 (01) : 35 - 50